Persistent IL-2 Receptor Signaling by IL-2/CD25 Fusion Protein Controls Diabetes in NOD Mice by Multiple Mechanisms

Low-dose interleukin-2 (IL-2) represents a new therapeutic approach to regulate immune homeostasis to promote immune tolerance in patients with autoimmune diseases, including type 1 diabetes. We have developed a new IL-2–based biologic, an IL-2/CD25 fusion protein, with greatly improved pharmacokine...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes
Autori principali: Ward, Natasha C., Lui, Jen Bon, Hernandez, Rosmely, Yu, Liping, Struthers, Mary, Xie, Jenny, Santos Savio, Alicia, Dwyer, Connor J., Hsiung, Sunnie, Yu, Aixin, Malek, Thomas R.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Diabetes Association 2020
Soggetti:
Immunology and Transplantation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7576568/
https://ncbi.nlm.nih.gov/pubmed/32843568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db20-0186
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi